algeldrate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4250 21645-51-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aluminum hydroxide
  • algeldrate
  • aluminum hydroxide hydrate
  • aluminium hydroxide
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
  • Molecular weight: 78.00
  • Formula: AlH3O3
  • CLOGP:
  • LIPINSKI: None
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS:
  • ROTB: 0

Drug dosage:

DoseUnitRoute
5 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 9, 1983 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 106.36 12.70 88 12455 40783 46632736
Hyponatraemia 97.76 12.70 128 12415 101204 46572315
Schizoaffective disorder 71.18 12.70 23 12520 1429 46672090
Acute kidney injury 66.64 12.70 175 12368 235680 46437839
Drug ineffective 49.67 12.70 66 12477 677772 45995747
Confusional state 44.42 12.70 118 12425 159774 46513745
Sinus rhythm 31.36 12.70 10 12533 595 46672924
End stage renal disease 29.83 12.70 19 12524 5867 46667652
Rhinovirus infection 29.72 12.70 16 12527 3620 46669899
Hepatocellular injury 29.50 12.70 38 12505 29484 46644035
Right aortic arch 29.41 12.70 8 12535 272 46673247
Rheumatoid arthritis 29.25 12.70 14 12529 240201 46433318
Completed suicide 28.55 12.70 3 12540 145917 46527602
Congenital arterial malformation 27.27 12.70 8 12535 359 46673160
Abdominal pain upper 26.88 12.70 93 12450 145212 46528307
Agitation 25.51 12.70 50 12493 55365 46618154
Gastrooesophageal reflux disease 23.86 12.70 58 12485 74286 46599233
Renal injury 23.66 12.70 20 12523 9521 46663998
Clostridium difficile colitis 23.62 12.70 27 12516 18526 46654993
Cutaneous T-cell lymphoma 23.44 12.70 10 12533 1353 46672166
Electrocardiogram QT prolonged 23.25 12.70 46 12497 51279 46622240
Haematemesis 22.62 12.70 33 12510 28773 46644746
Inappropriate antidiuretic hormone secretion 22.28 12.70 23 12520 14079 46659440
Genitourinary symptom 21.91 12.70 5 12538 81 46673438
Dyspepsia 21.53 12.70 53 12490 68419 46605100
Acute left ventricular failure 20.93 12.70 8 12535 815 46672704
Drug hypersensitivity 20.70 12.70 21 12522 243804 46429715
Drug intolerance 20.44 12.70 7 12536 147042 46526477
Vomiting 19.36 12.70 196 12347 452598 46220921
Drug level increased 18.84 12.70 24 12519 18417 46655102
Odynophagia 18.69 12.70 15 12528 6647 46666872
Coma scale abnormal 17.84 12.70 13 12530 4993 46668526
Hepatitis cholestatic 16.57 12.70 14 12529 6663 46666856
Acute pulmonary oedema 16.48 12.70 15 12528 7876 46665643
Morbid thoughts 16.46 12.70 6 12537 536 46672983
Lung disorder 16.32 12.70 36 12507 43268 46630251
False positive investigation result 16.31 12.70 6 12537 550 46672969
Toxicity to various agents 16.04 12.70 20 12523 211746 46461773
Gastritis 15.79 12.70 31 12512 34347 46639172
Drug interaction 15.23 12.70 100 12443 202994 46470525
Pharyngeal paraesthesia 15.04 12.70 7 12536 1163 46672356
Hallucination 15.00 12.70 38 12505 49913 46623606
General physical health deterioration 14.81 12.70 66 12477 115703 46557816
Faeces discoloured 14.31 12.70 20 12523 16767 46656752
Cerebellar haemorrhage 14.19 12.70 7 12536 1322 46672197
Immune thrombocytopenia 14.04 12.70 14 12529 8227 46665292
Melanoderma 14.01 12.70 4 12539 163 46673356
Adrenal mass 13.90 12.70 6 12537 835 46672684
Acute cutaneous lupus erythematosus 13.54 12.70 4 12539 184 46673335
Prurigo 13.39 12.70 6 12537 914 46672605
Pancreatitis acute 13.38 12.70 24 12519 24848 46648671
Troponin T increased 13.33 12.70 6 12537 923 46672596
Acute respiratory failure 13.05 12.70 26 12517 29112 46644407
Antipsychotic drug level increased 13.02 12.70 9 12534 3183 46670336

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypophosphataemic osteomalacia 48.98 13.59 10 7104 106 29945258
Hepatocellular injury 36.12 13.59 37 7077 25434 29919930
Chronic kidney disease 33.38 13.59 43 7071 37795 29907569
Mesothelioma 26.26 13.59 8 7106 464 29944900
Gastrooesophageal reflux disease 24.38 13.59 34 7080 32221 29913143
Hypercalciuria 22.68 13.59 6 7108 208 29945156
Craniotabes 22.57 13.59 4 7110 18 29945346
End stage renal disease 18.87 13.59 15 7099 7420 29937944
Hyponatraemic seizure 17.27 13.59 4 7110 79 29945285
Crystal urine 17.18 13.59 4 7110 81 29945283
Violence-related symptom 17.13 13.59 6 7108 541 29944823
Gastrointestinal necrosis 16.28 13.59 10 7104 3279 29942085
IVth nerve paresis 16.20 13.59 3 7111 18 29945346
Lower respiratory tract infection 15.65 13.59 25 7089 26689 29918675
Abdominal pain upper 15.53 13.59 41 7073 62510 29882854
Blood parathyroid hormone decreased 13.95 13.59 5 7109 482 29944882
Dysphagia 13.90 13.59 37 7077 56661 29888703
Toxicity to various agents 13.87 13.59 13 7101 177170 29768194
Blood fibrinogen decreased 13.68 13.59 6 7108 983 29944381

Pharmacologic Action:

SourceCodeDescription
ATC A02AB01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Aluminium compounds
ATC A02AB02 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Aluminium compounds
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D000863 Antacids
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:65265 antacids
CHEBI has role CHEBI:79314 flame retardants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Heartburn indication 16331000
Duodenal ulcer disease indication 51868009 DOID:1724
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Gastric ulcer indication 397825006 DOID:10808
Gastric Hypersecretory Conditions indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.51 acidic
pKa2 4.99 acidic
pKa3 5.47 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
03J11K103C UNII
4018607 VUID
N0000146920 NUI
D02807 KEGG_DRUG
1330-44-5 SECONDARY_CAS_RN
4017984 VANDF
4018607 VANDF
4019302 VANDF
C0002371 UMLSCUI
CHEBI:33130 CHEBI
CHEMBL3833310 ChEMBL_ID
CHEMBL1200706 ChEMBL_ID
DB06723 DRUGBANK_ID
D000536 MESH_DESCRIPTOR_UI
6328211 PUBCHEM_CID
1945 INN_ID
612 RXNORM
4159 MMSL
5582 MMSL
7537 MMSL
d00978 MMSL
001123 NDDF
007943 NDDF
273944007 SNOMEDCT_US
725733004 SNOMEDCT_US
768557001 SNOMEDCT_US
80399002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Good Sense antacid HUMAN OTC DRUG LABEL 3 0113-0340 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
Good Sense AntacidRegular Strength HUMAN OTC DRUG LABEL 3 0113-0357 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Good Sense AntacidMaximum Strength HUMAN OTC DRUG LABEL 3 0113-0588 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
good sense antacid HUMAN OTC DRUG LABEL 3 0113-0851 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC monograph final 14 sections
Mag-AL Plus HUMAN OTC DRUG LABEL 3 0121-1761 SUSPENSION 200 mg ORAL OTC monograph final 14 sections
Mag-AL PlusXS HUMAN OTC DRUG LABEL 3 0121-1762 SUSPENSION 400 mg ORAL OTC monograph final 15 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0094 LIQUID 95 mg ORAL OTC monograph final 13 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0095 LIQUID 254 mg ORAL OTC monograph final 13 sections
GavisconRegular Strength HUMAN OTC DRUG LABEL 2 0135-0096 TABLET, CHEWABLE 80 mg ORAL NDA 15 sections
GavisconExtra Strength HUMAN OTC DRUG LABEL 2 0135-0098 TABLET, CHEWABLE 160 mg ORAL OTC monograph final 15 sections
GavisconExtra Strength HUMAN OTC DRUG LABEL 2 0135-0430 TABLET, CHEWABLE 160 mg ORAL OTC monograph final 15 sections
GAVISCON HUMAN OTC DRUG LABEL 2 0135-0574 LIQUID 254 mg ORAL OTC monograph final 13 sections
Antacid Mint HUMAN OTC DRUG LABEL 3 0363-0432 SUSPENSION 200 mg ORAL OTC MONOGRAPH FINULLL 14 sections
Antacid antigasMaximum Strength HUMAN OTC DRUG LABEL 3 0363-0528 LIQUID 800 mg ORAL OTC MONOGRAPH FINULLL 15 sections
FAST ACTING Heartburn Relief HUMAN OTC DRUG LABEL 2 0363-1155 TABLET, CHEWABLE 160 mg ORAL OTC monograph final 12 sections
ADVANCED REGULAR STRENGTH ANTACID HUMAN OTC DRUG LABEL 3 0363-1639 SUSPENSION 200 mg ORAL OTC monograph final 10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS HUMAN OTC DRUG LABEL 3 0363-1691 SUSPENSION 400 mg ORAL OTC monograph final 10 sections
REGULAR STRENGTH ANTACID ANTIGAS HUMAN OTC DRUG LABEL 3 0363-2628 SUSPENSION 200 mg ORAL OTC monograph final 10 sections
Walgreens Fast Acting Heartburn Relief Extra Strength HUMAN OTC DRUG LABEL 2 0363-7630 LIQUID 254 mg ORAL OTC monograph final 13 sections
ALMACONE DOUBLE STRENGTH HUMAN OTC DRUG LABEL 3 0536-0015 SUSPENSION 400 mg ORAL OTC monograph final 10 sections
ALMACONE ANTACID ANTIGAS HUMAN OTC DRUG LABEL 3 0536-0025 SUSPENSION 200 mg ORAL OTC monograph final 10 sections
Aluminum Hydroxide HUMAN OTC DRUG LABEL 1 0536-0091 LIQUID 320 mg ORAL OTC monograph final 10 sections
rugby almacone HUMAN OTC DRUG LABEL 3 0536-1185 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Antacid Human OTC Drug Label 3 0536-1293 LIQUID 400 mg ORAL OTC MONOGRAPH FINULLL 12 sections
REGULAR STRENGTH ANTACID/ANTIGAS HUMAN OTC DRUG LABEL 3 0536-1317 SUSPENSION 400 mg ORAL OTC monograph final 10 sections
MAXIMUM STRENGTH ANTACID/ ANTIGAS HUMAN OTC DRUG LABEL 3 0536-1318 SUSPENSION 800 mg ORAL OTC monograph final 10 sections
Almacone HUMAN OTC DRUG LABEL 3 0536-3504 TABLET, CHEWABLE 200 mg ORAL OTC monograph final 12 sections
MI-ACID REGULAR STRENGTH HUMAN OTC DRUG LABEL 3 0904-0004 SUSPENSION 200 mg ORAL OTC monograph final 9 sections
MI-ACID MAXIMUM STRENGTH HUMAN OTC DRUG LABEL 3 0904-0005 SUSPENSION 400 mg ORAL OTC monograph final 10 sections